| Literature DB >> 34422359 |
Zhiqiang Wang1,2, Zhengdao Lai1,3, Xiaoxian Zhang1, Peikai Huang1,4, Jiaxing Xie1, Qian Jiang1, Qingling Zhang1, Kian Fan Chung5.
Abstract
BACKGROUND: Despite substantial evidence on the contribution of the diversity of the gut microbiome to the pathogenesis of asthma and allergic diseases, little is known about their relationship with asthma severity and/or clinical phenotypes. We analyzed the difference in composition of the gut microbiome between subjects with asthma and healthy subjects and explored its role in the development of asthma.Entities:
Keywords: Gut microbiome; asthma; phenotype
Year: 2021 PMID: 34422359 PMCID: PMC8339736 DOI: 10.21037/jtd-20-2189
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Sociodemographic characteristics of subjects determined by the degree of clinical symptoms
| Characteristics | Severe asthma group | Non-severe asthma group | Healthy group | P value |
|---|---|---|---|---|
| Sample size (%) | 15 (34.1) | 14 (31.8) | 15 (34.1) | – |
| Female (%) | 9 (60.0) | 8 (57.1) | 8 (53.3) | 0.76 |
| BMI (kg/m2) | 24.5±0.7 | 24.2±0.7 | 19.8±2.4 | 0.105 |
| Age (years) | 49±3.7 | 55±3.5 | 52±7.3 | 0.027# |
| Asthma duration (years) | 9.8 (2, 17.6) | 12.2 (5.8, 18.6) | – | 0.093 |
| Acute attacks (times/year) | 0 (0.2, 1.8) | 0.5 (0.2, 0.9) | – | 0.852 |
| Nasal disease duration (years) | 8.5 (0.6, 16.4) | 13.1 (6.2, 20) | – | 0.364 |
| OCS (sample size, %) | ||||
| 0 mg | 10 (66.7) | 11 (78.6) | – | 0.602 |
| 0–10 mg | 2 (20.0) | 1 (7.1) | – | 0.602 |
| >10 mg | 3 (13.3) | 2 (14.3) | – | 0.602 |
| $ ICS | 3 (2.9, 3) | 2.6 (2.4, 2.6) | – | <0.001& |
| Sputum eosinophils (%) | 17.6±5.6 | 6.8±5.7 | 1.5±1 | <0.001*# |
| Sputum neutrophils (%) | 46.3±6.5 | 65.5±9.5 | 68±8.3 | 0.208 |
| ACT score | 23±2.4 | 23±0.3 | – | 0.216 |
| FVC%-predicted (%) | 88.3±4 | 90±6.5 | 92±3.8 | 0.406 |
| FEV1%-predicted (%) | 72.7±6.1 | 81±6.9 | 94±5.4 | <0.001*# |
| FEV1/FVC ratio | 69.3±2.7 | 67.9±2.6 | 87.2±3.3 | <0.001*# |
| PEF%-predicted (%) | 78.4±5.7 | 77±9.2 | 101±8 | 0.009# |
| FEF25-75%-predicted (%) | 19.3±5.2 | 35.5±5.1 | 81.5±4.5 | <0.001*# |
| MEF75%-predicted (%) | 55.6±6.8 | 47±9.9 | 94±12.6 | 0.002*# |
| MEF50%-predicted (%) | 38.8±5.8 | 41.5±5.7 | 78±10.9 | <0.001*# |
| MEF25%-predicted (%) | 26.7±5 | 42±5.2 | 82±6.4 | <0.001*#& |
| Blood eosinophils (%) | 4.6±1.3 | 3.4±0.5 | 1.6±0.2 | <0.001*# |
| $Total IgE (IU/mL) | 7.±0.6 | 7.5±0.5 | 4.6±0.5 | <0.001*# |
| Atopy (%) | 9 (60.0) | 5 (35.7) | 0 | 0.048& |
*, severe asthma (SA) group vs. healthy group; #, non-severe asthma (NSA) group vs. Healthy group; &, SA group vs. NSA group; Inhaled corticosteroid (ICS) was normalized to budesonide. $, logarithmic transformation was used because data of Inhaled corticosteroid (ICS) dose and serum total IgE presented skewed distribution. Data expressed as mean ± standard deviation, or median (interquartile range), or percentage (%). P values were determined using t test, Mann-Whitney U test, or chi-square test among two groups and by using LSD, Bonferroni, and Kruskal-Wallis tests among three groups. ICS, inhale corticosteroid, OCS, oral corticosteroid, BMI, body mass index, FVC%-pred, forced vital capacity per predicted, FEV1%-predicted: Forced expired volume in one second per predicted, FEV1/FVC ratio, forced expiratory volume in one second to forced vital capacity ratio, PEF%-predicted, peak expiratory flow rate per predicted, FEF25–75%-predicted, force expiratory flow from 25–75% of FVC per predicted, MEF75%-predicted, maximal expiratory flow after 75% of the FVC per predicted, MEF50%-predicted, maximal expiratory flow after 50% of the FVC per predicted, MEF25%-predicted, maximal expiratory flow after 25% of the FVC per predicted.
Figure 1Stacked bar chart showing bacterial composition (median values) at the phylum level in the subjects with severe asthma (SA), subjects with non-severe asthma (NSA), and healthy subjects. Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria contributed over 90% of the total sequences in all three groups.
Relative abundances of different bacteria at the family level
| Level | Bacterial name | Median value | P value | |||||
|---|---|---|---|---|---|---|---|---|
| SA | NSA | Healthy | SA | SA | NSA | |||
| Family |
| 0.228 (0.056, 0.400) | 0.004 (−0.002, 0.010) | 0.156 (0.010, 0.301) | 0.016 | 0.558 | 0.416 | |
|
| 0.066 (−0.004, 0.135) | 0.011 (−0.002, 0.023) | 0.020 (−0.002, 0.043) | 0.023 | 0.060 | 1 | ||
|
| 0.024 (−0.007, 0.055) | 0.026 (0.015, 0.037) | 0.044 (0.018, 0.069) | 0.311 | 0.022 | 0.934 | ||
|
| 0.099 (0.065, 0.133) | 0.143 (0.111, 0.175) | 0.060 (0.029, 0.092) | 0.082 | 1 | 0.024 | ||
SA, severe asthma; NSA, non-severe asthma; P values were determined by Spearman’s tests.
Figure 2Correlations of relative abundances of bacteria among the non-severe asthma (NSA) and severe asthma (SA) groups (A), healthy and severe asthma (SA) groups (B), and healthy and non-severe asthma (NSA) groups (C). The value of zero indicates a similar percentage contribution of the bacterial family between the groups. A positive value for a bacterial family indicates higher percentage abundance in the group (right side), and a negative value indicates higher abundance in the group (left side). * indicates the statistical significance between two groups in the relative abundance of bacteria (Mann-Whitney U test, P<0.05).
Figure 3Scatter plots and correlations. (A) Scatter plot of eosinophil count (%) in induced sputum and relative of Veillonellaceae in fecal samples of subjects from the non-severe asthma (NSA) group. (B) Scatter plot of neutrophil count (%) in induced sputum and relative abundance of Lachnospiraceae in fecal samples of subjects from the NSA group. (C) Scatter plot of mid-expiratory flow 25% (MEF25%) predicted (%) and relative abundance of Veillonellaceae in fecal samples of subjects from the severe asthma (SA) group. (D) Scatter plots of body mass index and relative abundance of Acidaminococcaceae in fecal samples of subjects from the SA group (Spearman’s rank correlation coefficient, P<0.05).
Demographic and clinical characteristics of the recruited subjects classified by serum IgE levels
| Characteristics | High-IgE group | Low-IgE group | Healthy group | P value |
|---|---|---|---|---|
| Sample (%) | 21 (47.7) | 8 (18.2) | 15 (34.1) | – |
| Female (%) | 14 (66.7) | 3 (37.5) | 8 (53.3) | 0.218 |
| BMI (kg/m2) | 23.3±0.5 | 24.3±0.8 | 22.5±1.1 | 0.202 |
| Asthma duration (years) | 9.5 (5.1, 13.8) | 12.8 (3.3, 22.2) | – | 0.518 |
| Acute attacks (times/years) | 1.1 (0.5, 1.7) | 0 | – | 0.005& |
| Nasal disease duration (years) | 9.3 (5,13.6) | 8.9 (0.1, 17.6) | – | 0.549 |
| OCS (sample size, %) | 7 (33.3) | 0 (0) | – | 0.142 |
| $ICS | 3.2 (2.5, 3.4) | 2.9 (2.8, 3.1) | – | 0.401 |
| Sputum eosinophils (%) | 23.8±4.5 | 11.2±6.3 | 1.2±0.5 | <0.001* |
| Sputum neutrophils (%) | 53.4±4.9 | 36.4±11 | 55.9±8.9 | 0.305 |
| ACT score | 22.7±0.3 | 23.1±0.2 | – | 0.684 |
| FVC%-predicted (%) | 88.1±4 | 92±4.1 | 96.8±2.8 | 0.400 |
| FEV1%-predicted (%) | 72±5 | 72±5.3 | 95.9±2.9 | 0.004*# |
| FEV1/FVC ratio | 66.4±2.5 | 65.3±4.1 | 84.3±2.3 | <0.001*# |
| PEF%-predicted (%) | 75.6±5.5 | 83.2±9 | 96.8±5.8 | 0.09 |
| FEF25-75%-predicted (%) | 36±4.6 | 35±5.4 | 79.7±5.8 | <0.001*# |
| MEF75%-predicted (%) | 55±7.1 | 43±8 | 85±9.3 | 0.010# |
| MEF50%-predicted (%) | 39.4±5.1 | 41.1±7.4 | 80.4±6 | <0.001*# |
| MEF25%-predicted (%) | 36±4.3 | 30.5±3.8 | 75.4±4 | <0.001*# |
| Blood eosinophils (%) | 5.6±0.8 | 3.3±0.4 | 1.3±0.2 | <0.001* |
| $Total IgE (IU/mL) | 2.4 (2.3, 2.7) | 1.6 (1, 1.8) | 1.3 (0.9, 1.5) | <0.001*& |
*, high-IgE asthma (HEA) group vs. healthy group; #, low-IgE asthma (LEA) group vs. healthy group; &, HEA group vs. LEA group, Inhaled corticosteroid (ICS) was normalized to budesonide; $, logarithmic transformation was used because ICS dose and serum Total IgE data presented skewed distribution. Data expressed as mean ± standard deviation, or median (interquartile range), or percentage (%). P values were determined using t test, Mann-Whitney U test, or chi-square test among two groups and by using LSD, Bonferroni, and Kruskal-Wallis tests among three groups. ICS, inhale corticosteroid, OCS, oral corticosteroid, BMI, body mass index, FVC%-pred, forced vital capacity per predicted, FEV1%-predicted: Forced expired volume in one second per predicted, FEV1/FVC ratio, forced expiratory volume in one second to forced vital capacity ratio, PEF%-predicted, peak expiratory flow rate per predicted, FEF25–75%-predicted, force expiratory flow from 25–75% of FVC per predicted, MEF75%-predicted, maximal expiratory flow after 75% of the FVC per predicted, MEF50%-predicted, maximal expiratory flow after 50% of the FVC per predicted, MEF25%-predicted, maximal expiratory flow after 25% of the FVC per predicted.
Figure 4Stacked bar chart showing bacterial composition (median values) at the phylum level in the high-immunoglobulin E (IgE) asthma subjects (HEA), low-IgE asthma subjects (LEA), and healthy subjects. A core gut microbiome consisting of Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria was identified in all three groups.
Relative abundances of different bacteria at the family level
| Level | Bacteria name | Median value | P value | |||||
|---|---|---|---|---|---|---|---|---|
| HEA | LEA | Healthy | HEA | HEA | LEA | |||
| Class | | 0.032 (0.018, 0.045) | 0.076 (0.034, 0.119) | 0.047 (0.029, 0.066) | 0.018 | 0.556 | 0.481 | |
| Order | | 0.032 (0.018, 0.045) | 0.076 (0.034, 0.119) | 0.047 (0.029, 0.066) | 0.018 | 0.556 | 0.481 | |
| Family | | 0.029 (0.007, 0.051) | 0.014 (0, 0.027) | 0.05 (0.017, 0.083) | 1 | 0.093 | 0.050 | |
| | 0.031 (0.018, 0.045) | 0.076 (0.033, 0.119) | 0.047 (0.029, 0.065) | 0.019 | 0.536 | 0.518 | ||
HEA, high IgE group; LEA, low IgE group; P values were determined using Spearman’s tests.
Figure 5Correlations of relative abundances of bacteria among low-IgE asthma groups (LEA) and high-IgE asthma (HEA) groups (A,B,D), low-IgE asthma (LEA) groups and the healthy group (C). The value of zero indicates a similar percentage contribution of the bacterial family in both groups. A positive value for a bacterial family represents higher percentage abundance in the group on the right, and a negative value indicates higher abundance in the group on the left. * indicates statistically significant difference in the relative abundance of bacteria between the two groups (Mann-Whitney U test, P<0.05).
Figure 6Scatter plots and correlations. (A) Scatter plot of the relative abundance of Betaproteobacterial class, Burkholderiales order, and Alcaligenaceae family shows positive correlations with nasal disease and total immunoglobulin E (IgE) in the high-IgE asthma (HEA) group. (B) Scatter plot of the relative abundance of Betaproteobacterial class, Burkholderiales order, and Alcaligenaceae family shows negative correlations with the dose of oral steroids and sputum eosinophils. (C) Scatter plot of the relative abundance of Betaproteobacterial class, Burkholderiales order, and Alcaligenaceae family shows positive correlations with blood eosinophils in the low-IgE asthma (LEA) group (Spearman’s rank correlation coefficient, P<0.05).
Principal component analysis of the clinical features and relative abundance of microbiota
| Principal component (% of total variance) | |||||
|---|---|---|---|---|---|
| 1 (32.2%) | 2 (16.0%) | 3 (13.7%) | 4 (11.5%) | 5 (10.2%) | |
| Diagnosis | 0.407 | 0.188 | 0.701 | −0.332 | −0.064 |
| Duration | 0.143 | 0.862 | −0.030 | −0.094 | −0.085 |
| Nasal disease duration | 0.020 | 0.825 | 0.247 | 0.031 | 0.072 |
| Inhale corticosteroid | −0.848 | −0.063 | −0.140 | 0.212 | −0.047 |
| Sputum neutrophilia | 0.833 | 0.096 | 0.128 | 0.124 | 0.109 |
| Prevotellaceae | −0.084 | −0.089 | −0.930 | −0.074 | −0.131 |
| Acidaminococcaceae | 0.121 | −0.017 | 0.080 | 0.010 | 0.982 |
| Veillonellaceae | −0.045 | −0.041 | −0.045 | 0.961 | 0.008 |